Gelonghui, April 15 | The General Office of the State Council issued the ‘Several Opinions on Improving the Drug Pricing Mechanism.’ Citi stated that this is the most significant guiding document on drug pricing issued by the central government since 2015, viewing it as a crucial signal of the government’s clear commitment to supporting globally competitive domestic pharmaceutical and biopharmaceutical industries. The policy aims to allow the market to play a more decisive role in the formation of drug prices. Key innovative pharmaceutical companies and biopharmaceutical firms are expected to benefit, such as Hengrui Pharma, CSPC Pharma, Innovent Bio, and other multinational corporations.